CLAIMS

What is claimed is :

1. A single dosage composition comprising a 5-HT$_{2A}$ antagonist, a norepinephrine-dopamine reuptake inhibitor, and a pharmaceutically acceptable carrier.

2. A method of treating hypoactive sexual desire disorder (HSDD) in a subject comprising administering to the subject a 5-HT$_{2A}$ antagonist and a norepinephrine-dopamine reuptake inhibitor.

3. A method of treating a diagnostic and statistical manual of mental disorders (DSM-IV) disorder in a subject comprising administering to the subject a 5-HT$_{2A}$ antagonist and a norepinephrine-dopamine reuptake inhibitor.

4. A method of treating erectile dysfunction (ED) in a subject comprising administering to the subject a 5-HT$_{2A}$ antagonist and a norepinephrine-dopamine reuptake inhibitor.

5. A method of making a composition comprising combining a 5-HT$_{1A}$ receptor agonist and a pharmaceutically acceptable carrier such that the composition comprises a range of 25-450 of a 5-HT$_{1A}$ receptor agonist and a norepinephrine-dopamine reuptake inhibitor.

6. A method of making a composition comprising combining a 5-HT$_{2A}$ antagonist and a pharmaceutically acceptable carrier such that the composition comprises a range of 25-450 mg of a 5-HT$_{2A}$ antagonist and a norepinephrine-dopamine reuptake inhibitor.